Table 4.
Association of baseline characteristics and COVID-19 treatment with presence of symptoms at 6 weeks postdischarge.
| Variables | Whole cohort (N=120) | ICUa (n=50) | Non-ICU (n=70) | |||||||||
|
|
Symptoms (n=73) | No symptoms (n=47) |
P value |
Symptoms (n=35) | No symptoms (n=15) |
P value |
Symptoms (n=38) | No symptoms (n=32) |
P value |
|||
| Age (years), mean (SD) | 56.71 (6.16) | 52.21 (19.52) | .17 | 61.34 (12.79) | 54.8 (13.49) | .11 | 52.45 (17.86) | 51 (21.87) | .76 | |||
| Gender, n (%) |
|
|
.16 |
|
|
.04 |
|
|
.50 | |||
|
|
Male | 37 (56.1) | 29 (43.9) |
|
22 (61.1) | 14 (38.9) |
|
15 (50.0) | 15 (50.0) |
|
||
|
|
Female | 36 (66.7) | 18 (33.3) |
|
13 (92.9) | 1 (7.1) |
|
23 (57.5) | 17 (42.5) |
|
||
| Charlson Comorbidity Index, mean (SD) | 2.30 (1.91) | 1.79 (2.04) | .16 | 2.74 (1.85) | 1.87 (2.26) | .16 | 1.89 (1.90) | 1.75 (1.96) | .76 | |||
| Antivirals, n (%) | ||||||||||||
|
|
During hospital stay | 55 (70.5) | 23 (29.5) | .006 | 31 (70.5) | 13 (29.5) | .51 | 24 (70.6) | 10 (29.4) | .007 | ||
|
|
During discharge | 4 (57.1) | 3 (42.9) | .57 | 2 (50.0) | 2 (50.0) | .34 | 2 (66.7) | 1 (33.3) | .50 | ||
| Anticoagulants, n (%) | ||||||||||||
|
|
During hospital stay | 51 (64.6) | 28 (35.4) | .17 | 29 (69.0) | 13 (31.0) | .54 | 22 (59.5) | 15 (40.5) | .24 | ||
|
|
During discharge | 31 (70.5) | 13 (29.5) | .07 | 20 (69.0) | 9 (31.0) | .55 | 11 (73.3) | 4 (26.7) | .08 | ||
| Steroids, n (%) | ||||||||||||
|
|
During hospital stay | 45 (75.0) | 15 (25.0) | .001 | 33 (68.8) | 15 (31.3) | .48 | 12 (100.0) | 0 (0) | .001 | ||
|
|
During discharge | 16 (66.7) | 8 (33.3) | .60 | 11 (57.9) | 8 (42.1) | .12 | 5 (100.0) | 0 (0) | .04 | ||
aICU: intensive care unit.